Resources

This is not one patient’s disaster averted but what I have experienced working in the field of diabetes and obesity for years. Many times patients who are taking glucose lowering and/or anti obesity medications will report different GI complaints-such as bloating, diarrhea, constipation, nausea, vomiting, and GERD. They tell me they are going to see a gastroenterologist for an evaluation.

In part 1 of this Exclusive Interview, Dr. Swapnil N. Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the contribution of the DPP4’s to the reduction of hypoglycemic risk.

In this week's Homerun Slides, types of hypertension and defining Cushing's Syndrome.

OSA and diabetes-related complications: Recently, there has been increasing interest in the association between OSA and diabetes-related complications. There is one cross-sectional published study regarding the association between OSA and macrovascular complications in T2DM, but several studies have examined the association between microvascular complications and OSA in T2DM. Most of these studies are cross-sectional in nature but more recently prospective studies proving causality have been published. Many of these studies fail to adjust for many of the possible confounders.

More specific classifications for the disease could lead to more personalized treatments in the future. Is it time?

Study confirms recent guideline changes on metformin use in moderate-to-severe chronic kidney disease.

Researchers complete examination of class of type 2 medication.

Very low incidence of end stage renal disease (ESRD) was found in patients with childhood-onset diabetes type 1 in Norway.

Management of obesity by dietary, pharmacologic, and surgical intervention can provide very positive results.

Which of the classes of drugs have you seen the best results in lowering A1c for type 2 diabetes? DPP-4, GLP-1, or SGLT-2? Follow the link to share your response.